10-Q: Encision Inc. Reports Q3 2024 Results with Revenue Decline and Increased Net Loss

Encision Inc. reported a decrease in product revenue and an increased net loss for the third quarter of fiscal year 2024, alongside ongoing efforts to improve internal controls and expand market reach.

Summary

• Encision Inc. reported a net loss of $207,130 for the three months ended December 31, 2023, compared to a net loss of $216,334 for the same period in 2022.
• Product revenue decreased by 7% to $1,561,103 for the quarter, while service revenue was $20,461, compared to no service revenue in the prior year.
• Gross profit decreased by 19% to $727,239, with a gross margin of 46% compared to 53% in the prior year due to increased inventory reserves.
• For the nine months ended December 31, 2023, the net loss was $355,112, compared to a net loss of $231,053 in 2022.
• Product revenue for the nine-month period decreased by 3% to $4,927,069, and service revenue decreased to $134,269 from $458,633 in the prior year.
• The company's cash decreased by $89,727 to $99,239 as of December 31, 2023, and working capital decreased to $1,643,901.
• The company has a line of credit up to $1,000,000, restricted by eligible accounts receivable.
• Management believes that current cash resources and the line of credit will be sufficient to meet cash requirements for the next twelve months.
• The company is working to remediate material weaknesses in internal controls over financial reporting.

Sentiment

Score: 4

Explanation: The document presents a mixed picture with declining revenue and increased losses, but also highlights ongoing efforts to improve operations and expand market reach. The need for potential capital raises and the material weakness in internal controls are concerning, leading to a lower sentiment score.

Positives

• The company generated $155,352 of cash in operating activities during the nine months ended December 31, 2023.
• The company has a line of credit available up to $1,000,000, restricted by eligible accounts receivable.
• Management believes that current cash resources and the line of credit will be sufficient to meet cash requirements for the next twelve months.
• The company is actively working to remediate material weaknesses in its internal controls over financial reporting.
• Sales and marketing expenses decreased by 17% for both the quarter and nine months ended December 31, 2023, compared to the same periods in 2022.

Negatives

• Product revenue decreased by 7% for the quarter and 3% for the nine months ended December 31, 2023, compared to the same periods in 2022.
• Gross profit decreased by 19% for both the quarter and nine months ended December 31, 2023, compared to the same periods in 2022.
• The company's net loss increased to $355,112 for the nine months ended December 31, 2023, compared to $231,053 for the same period in 2022.
• The company's cash balance decreased to $99,239 as of December 31, 2023, from $188,966 at the end of the previous fiscal year.
• Working capital decreased to $1,643,901 as of December 31, 2023, from $1,993,777 at the end of the previous fiscal year.
• The company has identified material weaknesses in its internal controls over financial reporting.
• Gross margin on product net revenue decreased to 46% for the quarter ended December 31, 2023, from 53% for the same period in 2022.

Risks

• The company has an accumulated deficit of $22,208,375 as of December 31, 2023.
• The company may need to seek additional capital if liquidity is diminished due to operating losses.
• The company's ability to increase sales depends on the efficiency of its sales representatives and market acceptance of its products.
• The company's financial results are subject to fluctuations due to product sales mix, sales volume, and service revenue.
• The company is subject to regulation by the FDA, and compliance issues could impact operations.
• The company's net operating loss carryforwards may be limited by changes in ownership interests.
• The company's estimates for inventory obsolescence and warranty costs may differ from actual results.
• The company's internal controls over financial reporting were not effective during the reporting period ended December 31, 2023.

Future Outlook

The company aims to increase sales of its AEM products, expand market awareness, and maximize the number of hospital and surgery center accounts switching to AEM instruments. They also plan to develop next-generation products and explore overseas markets and licensing opportunities. The company expects that the replacement sales of electrosurgical instruments and accessories will also increase as additional facilities adopt AEM technology.

Management Comments

• Management is developing plans to ensure that we have the working capital necessary to fund operations.
• We will increase our pricing on products to mitigate our higher material costs.
• Management concludes that it is probable that our cash resources and line of credit will be sufficient to meet our cash requirements for twelve months from the issuance of the unaudited condensed financial statements.
• Our objectives for the remainder of fiscal year 2024 are to optimize sales execution, to expand market awareness of the AEM technology and to maximize the number of additional hospital and surgery center accounts switching to AEM instruments while retaining existing customers.

Industry Context

The report highlights the challenges faced by medical device companies, including decreased surgical procedure volumes due to COVID resurgences and affordability issues. The company's focus on patient safety and its patented AEM technology aligns with the industry's increasing emphasis on reducing hospital-acquired conditions and improving surgical outcomes. The company is also addressing the market opportunity created by the increase in minimally-invasive surgery (MIS) and surgeons use of electrosurgery devices in these procedures.

Comparison to Industry Standards

• Encision's revenue decline contrasts with some larger medical device companies that have shown resilience or growth in the same period, such as Medtronic and Johnson & Johnson, which have diversified product portfolios and global reach.
• The company's gross margin of 46% for the quarter is lower than the industry average for medical device companies, which typically ranges from 50% to 70%, indicating potential pricing or cost management issues.
• The company's net loss and negative cash flow from operations are concerning compared to industry leaders that often report positive earnings and strong cash positions.
• Encision's reliance on a single technology (AEM) makes it more vulnerable to market shifts and competition compared to companies with broader product offerings.
• The company's ongoing efforts to remediate material weaknesses in internal controls are critical, as these issues can impact investor confidence and regulatory compliance, which are key benchmarks for public companies.

Related Party Transactions

• The company paid consulting fees of $12,094 and $25,822 to an entity owned by one of its board members during the three and nine months ended December 31, 2023 and 2022, respectively.

Stakeholder Impact

• Shareholders may be concerned about the company's declining revenue, increased losses, and the need for potential capital raises.
• Employees may be affected by the company's financial performance and any potential restructuring or cost-cutting measures.
• Customers may be impacted by the company's ability to maintain product quality and supply.
• Suppliers may be affected by the company's financial stability and ability to pay for goods and services.
• Creditors may be concerned about the company's ability to repay its debts.

Next Steps

• The company plans to optimize sales execution.
• The company plans to expand market awareness of the AEM technology.
• The company plans to maximize the number of additional hospital and surgery center accounts switching to AEM instruments while retaining existing customers.
• The company plans to develop next generation versions of the AEM product line.
• The company plans to explore overseas markets to assess opportunities for sales growth internationally.
• The company intends to explore opportunities to capitalize on its proven AEM technology via licensing arrangements and strategic alliances.
• The company will design and implement additional procedures during fiscal 2024 in order to assure that audit/accounting personnel are more involved with the Company's inventory activities and service revenue to monitor and earlier identify accounting issues that may be raised by the Company's ongoing activities.

Key Dates

Keywords

medical devices, electrosurgery, laparoscopic surgery, AEM technology, surgical instruments, financial results, internal controls, revenue, net loss, gross profit